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A B S T R A C T
Objectives: HBV infection typically leads to chronic hepatitis in newborns and some adults with
weakened immune systems. The mechanisms by which virus escapes immunity remain undeﬁned.
Regulatory dendritic cells (DCregs) contributing to immune escape have been described. We wondered
whether or not HBeAg as an immunomodulatory protein could induce DCreg which might subsequently
result into HBV persistence.
Methods: The immunophenotyping, T-cell activation and cytokine production were analyzed in HBeAg-
treated DCs from normal or cyclophosphamide (Cy)-induced immunocompromised mice.
Results: HBeAg tended to promote bone marrow derived DCs (BMDCs) from Cy-treated mice into
CD11bhighPIR-B+ regulatory DCs exhibiting the lowest T-cell stimulatory capacity and interleukin (IL)-
12p70 production compared with controls. Neutralization of IL-10 signiﬁcantly inhibited the regulatory
effect of these DCs on T-cell stimulation of mature DCs. After lipopolysaccharides (LPS) stimulation,
marked phosphorylation of Akt was detected in HBeAg treated DCs from immunocompromised mice.
Blocking the PI3K-Akt pathway by LY294002 led to an enhancement of IL-12 production. PI3K signalling
pathway appears to be involved in the decreased IL-12 secretion by HBeAg treated DCs.
Conclusions: These ﬁndings suggest that HBeAg may program the generation of a new DC subset with
regulatory capacity under the condition of immunosuppression, which may presumably contribute to
the persistent HBV infection.
 2016 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Chronic hepatitis B (CHB) is an ongoing worldwide health
problem, affecting more than 350 million people globally.1 The
persistent infection of hepatic B virus (HBV) is a major cause of
liver cirrhosis, hepatic failure and hepatocellular carcinoma. It is
widely accepted that immune tolerance is a possible key factor for
CHB, but its mechanisms remain elusive. One or more antigens of
HBV may utilize diverse pathways to suppress the anti-HBV
immune response and induce HBV-speciﬁc tolerance.
Hepatitis B e antigen (HBeAg), a secretory form of the
nucleocapsid antigen, is translated from the preC transcript,
sharing an overlapping reading frame with hepatitis B core* Corresponding author. Department of Gastroenterology, The First Afﬁliated
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license (http://creativecommons.org/licenses/by-nc-nd/4.0/).antigen(HBcAg).2 Although HBeAg is not necessary for infection
or replication of HBV,3 it is believed to be required for the
establishment of chronic infection and probably responsible for
the immunomodulation of host immune responses during CHB.4,5
HBV establishes chronic hepatitis mainly by vertical transmission
from HBeAg-positive mothers to neonates, as the immune system
of neonates has not yet fully developed.6 Signiﬁcantly higher
chronicity rate (up to 90%) is observed in this setting, whereas in
HBV infected adolescents or adults, 5%-10% lead to a chronic carrier
state.7 Interestingly, babies infected perinatally with an HBeAg-
negative mutant form of HBV experience an acute or fulminant
acute course of infection rather than a persistent infection.8 In
addition, studies have found that immunosuppressed persons
infected with HBV are more likely to develop chronicity.9,10 AASLD
guideline of CHB has categorized persons needing immunosup-
pressive therapy and HIV-infected individuals into high risk groups
that should be tested for HBV infection and immunized if
seronegative.1 Thus, the tremendous difference in chronicity rates
is supposed to be closely related to HBeAg and the immunologicciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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HBeAg under different immune status has not been studied
explicitly until now. There is a lack of well-established animal
models of immunosuppression to study the pathogenesis of CHB.
As the most potent antigen presenting cells (APCs), dendritic cells
(DCs) play a key role in the initiation and maintenance of speciﬁc
T-cell immunity.11–13 Studies have shown that defects in DC
function are important factors in the host-speciﬁc T-cell immune
tolerance to viral infection, rather than functional defects in T-or
B-cells.14,15 Additionally, DCs are not a single cell type, but rather a
heterogeneous population of cells with high developmental
plasticity. In recent years, considerable insight has been developed
into a new subset of DCs with regulatory function named regulatory
DCs (DCregs), and the role played by these DCregs in down-
regulating immune responses and inhibiting inﬂammation has been
shown in some in vivo models of autoimmune or inﬂammatory
diseases.16,17We wondered whether DCs could acquire a tolerogenic
or regulatory phenotype in response to speciﬁc stimuli of HBV,
which in turn aided viral immune escape. So far, the potential effects
of HBeAg on DCs have not been rigorously elucidated. We
hypothesized that HBeAg, as a recognized tolerogen, may direct
DCs to differentiate into DCreg contributing to the tolerance of CHB.
In the present study, we investigated the effects of HBeAg on
bone marrow derived DCs (BMDCs) from mice in different
immunologic status. The result showed that being incubated with
HBeAg promoted DCs from immunocompromised mice to
differentiate into a new regulatory DC subset that are phenotypi-
cally and functionally different from their classic conventional DCs.
These ﬁndings provide further understanding of the impact of
HBeAg on DCs and may ultimately beneﬁt the development of new
DC-based immunomodulatory strategies for chronic hepatitis B.
2. Methods
2.1. Mice and cyclophosphamide treatment
C57BL/6(B6) and BALB/c mice (6-8 weeks old, weighing 18-25 g)
were purchased from Shanghai Slac Laboratory Animal Center,
Chinese Academy of Sciences (Shanghai, China). Cyclophosphamide
(Cy) was purchased from Jiangsu Hengrui Medicine Co. (Lianyun-
gang, Jiangsu, China). The mice were all housed in speciﬁc pathogen-
free facilities and maintained under constant temperature
(20-22 8C), controlled humidity (45%-55%) and a 12-h light/dark
cycle (lights on from 08:00 to 20:00). All experimental procedures
were approved by the Institutional Animal Committee of Wenzhou
Medical University and all mice received care throughout the
experiment in accordance with ‘‘Guide for the Care and Use of
Laboratory Animals’’.
The B6 mice were randomly allocated into 2 treatment groups
in this study (n = 20 for each group). One group was administered
intraperitoneally with a single dose of 200 mg/kg body weight
(BW) of Cy 3 days before femurs and tibiae being removed and
puriﬁed from the surrounding muscle tissues. Another group of
healthy mice was kept as normal controls (normal group) and
injected intraperitoneally with PBS similarly. The dosage and
treatment regimens about Cy used here were based on the
previous studies of immunosuppressed model.18–20
2.2. Generation of bone marrow-derived dendritic cells and cell
cultures
BMDCs from the two groups were prepared according to
established protocols with minor modiﬁcation.21,22 Brieﬂy, cells
were gathered from C57BL/6 bone marrow and cultured at a
density of 2  106 cells/ml in 6-well plates in RPMI1640 (Gibico,
USA), supplemented with 10% fetal calf serum (Gibico, USA), 1%penicillin/streptomycin, 1 ng/ml of recombinant mouse IL-4 and
10 ng/ml GM-CSF(PeproTec, London; United Kingdom) at 37 8C,
5%CO2. On day 6, non-adherent and loosely adherent immature
DCs(iDCs) were harvested and sorted by CD11c magnetic microbe-
ads and a MiniMACS separator (Miltenyi Biotec, Germany) to
obtain highly puriﬁed DCs. The cell viability after magnetic beads
sorting was assayed with trypan blue staining. The percentage of
CD11c positive cells was detected by ﬂow cytometry.
HBeAg was purchased from Beijing Kewei clinical diagnostic
reagents Co, Ltd., Beijing, China. To investigate the inﬂuence of
HBeAg on DC, 5 mg/ml HBeAg was added into the CD11c+ cells for
24 h. In some instance, the cultures were supplemented with 100ng/
ml lipopolysaccharide (LPS, Sigma -Aldrich;USA) for another 24 h or
100 nM PI3K inhibitor LY294002 (Beyotime Institute of Biotechnol-
ogy, Haimen; China) for 1 hour in advance, then followed with LPS
stimulation.
2.3. Flow cytometry
To characterize and compare the phenotype of DC populations,
ﬂow cytometry was performed. DCs were harvested and washed.
The cells were then incubated in cold buffer and subsequently
stained for 30 min with the following APC-, PE-, FITC-labeled
monoclonal antibodies or appropriate isotype controls: CD11b,
Ia(BioLegend, USA), PIR, CD86(eBioscience, San Diego, USA). Stained
cells were analysed in an Elite ﬂow cytometer (Coulter, Hialeah, FL).
2.4. Real-time quantitative RT–PCR analysis of PIR-A and PIR-B
RNA was extracted from DCs by Trizol reagent (Invitrogen,
Carlsbad, CA, USA) and the cDNA synthesis of RT–PCR was performed
using a commercial kit (Toyobo, Osaka, Japan) according to the
manufacturer’s instructions. Then, the PCR reaction mixture was
prepared by SYBR Green Real-time PCR Master Mix-Plus (Toyobo,
Osaka, Japan). Ampliﬁcation of cDNA was performed with a common
forward primer (50-CCTGTGGAGCTCACAGTCTCAG-30) and the
PIR-A-speciﬁc primer (50-CCCAGAGTGTAGAACATTGAAGATG-30)
or PIR-B-speciﬁc primer (50-GTGTTCAGTTGTTCCCTTGACATGA-30).
Ampliﬁcation of b-actin transcription with the primers 50-CTG GCA
CCA CAC CTC CTA CA-30 and 50-AGT ACT TGC GCA CAG GAG GA-30
was performed as a control.
2.5. Allogeneic-mixed lymphocyte reactions (MLRs)
T-cells were isolated and puriﬁed from healthy BALB/c spleen
by nylon wool columns and CD4+ T isolation kit (Miltenyi
Biotec, Germany), according to the manufacturer’s instructions.
Primary MLRs were performed as previously described. Brieﬂy,
graded concentrations of DCs from different culture conditions
were co-cultured in U-bottom 96-well plates with constant
number of allogeneic T-cells (1  105cells/200 ml) at different
stimulator/responder(DC/T-cell) rations(1:5, 1:10, 1:20) for 96 h.
The T-cell stimulatory activity of DC populations in MLR was
expressed as stimulation index (SI) value and measured using CCK-
8 cell proliferation array kit (Beyotime Institute of Biotechnology,
Haimen, China), in accordance with the manufacturer’s instruc-
tion. SI values of the primary MLR consisting of naı¨ve 105 BALB/c
CD4+ T-cells, 104 mature DCs (mDCs) and indicated numbers of
HBeAg-treated DCs were detected to test the regulatory function.
In neutralizing cultures, anti-IL-10 antibodies (R&D Systems,
Minneapolis, MN) were used at the beginning of the MLR.
2.6. Cytokine production
The concentration of IL-12p70 and IL-10 in culture super-
natants of pure DCs under different treatments was estimated by
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kits (R&D Systems, Minneapolis, MN).
2.7. Western blotting
Expression of p-Akt and Akt were determined by western blot
according to standard protocols. The rabbit anti-Akt (Abcam, UK,
1:1000), rabbit anti-p-Akt (Cell Signalling, USA, 1:1000) and a
horse peroxidase (HRP) -conjugated secondary goat anti-rabbit
antibody (Biosharp, China, 1:5000) were used. Visualization was
achieved by chemiluminescence (ECL).
2.8. Statistical Analysis
All data were reported as mean  standard deviation (S.D.).
Statistical analysis was performed by Student t test or one-way ANOVA
followed by post-hoc tests (using LSD-t or Dunnett’s T3) for multi group
comparisons with SPSS18.0 program. All P values < 0.05 were consid-
ered signiﬁcant.
3. Results
3.1. HBeAg educates DCs to differentiate into a phenotypically distinct
population
The percentage of viable DCs detected with trypan blue staining
was not signiﬁcantly changed after puriﬁcation compared with
before in both two mice groups [(96.61  0.34) % vs (96.08  0.22)
%, P > 0.05; (96.28  0.23) % vs (96.15  0.25)%, P > 0.05]. More thanFigure 1. HBeAg drives differentiation of DCs into CD11bhighPIRhigh DCregs in vitro. (A)P
group). (B) DCs from normal or Cy-treated mice were stained with different mAbs and 
HBeAg, DCs were treated with LPS(100ng/ml) for 24 hrs. Then, the cells were harvested
mAbs; numbers in histograms indicate the gometric mean ﬂurescence). (C) Percentage95% cells were positive for CD11c as assessed by ﬂow cytometry
(Figure 1A).
To clarify the role of HBeAg in regulation of the phenotype of DCs
in the normal mice and Cy-induced immunocompromised mice, we
applied exogenous HBeAg(5 mg/ml) addition in DCs for 24 h. There
were dramatic enhancement in the expression of CD11b and paired
immunoglobulin-like receptor-A/B (PIR-A/B) on DCs from both
normal and immunocompromised mice (Fig. 1B). And Cy plus HBeAg
treated group showed a higher expression level of CD11b and PIR
than HBeAg treated DCs from normal mice. Besides, its proportion of
CD11B+PIR+ DCs(75.9%  5.8%) was also signiﬁcantly higher than
HBeAg group(63.3%  4.1%)(P < 0.05)(Fig. 1C). DC’s surface molecules,
including Ia and the costimulatory molecules CD86, all of which will be
greatly up-regulated during the DC maturation. However, HBeAg was
unable to change the expression of Ia and CD86. Furthermore, the
unique phenotype of high expression of CD11b and PIR on HBeAg
incubated DCs from Cy-treated mice remained unchanged even
stimulated with LPS(100ng/ml), thus indicating that such DCs exhibit
a relatively stable phenotype (Fig. 1B).
PIR-A and PIR-B are members of immunoglobin superfamily.
We investigated that there was an up-regulation of PIR positive
rate in DCs cultured with HBeAg for the ﬁrst time. PIR-B is known
as an inhibitory receptor, which consists of the activating-type PIR-
A. Then we examined the mRNA of PIR-A and PIR-B respectively to
detect which type dominantly expressed on cells by real-time
quantitative PCR. The PIR-B mRNA in both two HBeAg treated
groups increased signiﬁcantly (P < 0.05), compared with that of
the control groups. And the HBeAg plus Cy treated group showed a
higher level of PIR-B mRNA than that of HBeAg-treated DC fromercentages of CD11c positive cells after puriﬁcation (a, normal group; b, Cy-treated
analyzed by ﬂow cytometry in the presence or absence of HBeAg. With or without
 and analyzed by ﬂow cytometry. (Dotted line, isotype control; solid line, speciﬁc
s of CD11b+PIR+ cell in HBeAg-treated DCs from normal (a) or Cy-treated mice (b).
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signiﬁcantly difference among groups. LPS can induce higher PIR-A
expression and lower PIR-B expression. So we detected the changes
of PIR-A and PIR-B expression after the simulation of LPS
(Fig. 2B.C). The result showed HBeAg plus Cy-treated DCs remained
high expression of PIR-B without obvious change of PIR-A.
However, the PIR-A mRNA signiﬁcantly ascended after the
administration of LPS in the groups without HBeAg.
3.2. HBeAg treated DCs show reduced T-cell stimulatory capacity and
partially IL-10-dependent regulatory function
To further determine the functional properties of DCs, we
analyzed their T-cell stimulatory capacity in mixed lymphocyte
reaction (MLR) experiments. As expected, the T-cell stimulatory
capacity of immature DC (iDC) from both normal and Cy-treated
mice was very low in comparison to that observed for mature
DC (mDC). More importantly, the results showed that DCs from
both the two groups incubated with HBeAg tended to have a
considerably diminished T-cell stimulatory activity (P < 0.05) as
compared with mDC (Fig. 3A). And Cy + HBeAg group showed a
lower T-cell stimulatory capacity than HBeAg-treated
DCs(P < 0.05) at a DC:T ratio of 1:5 and 1:10. Our results showed
that HBeAg was not an efﬁcient inducer for DCs to generate T-cell
proliferation (Fig. 3A). In addition, to determine if these HBeAg-
treated DCs had regulatory capacity, we tested their effect on the
T-cell activation of mDCs.103 HBeAg-treated DCs from immuno-
compromised mice could suppress the MLR induced by 104 mDC
by almost 35%, and when mixed at a 1:1 ration, the degree of
suppression increased to approximately 50%(Fig. 3B). IL-10,
secreted by many kinds of cells with regulatory functions, can
induce T-cell unresponsiveness when present during T-cell
activation.19 Given that regulatory function of bone marrowFigure 3. Low T cell proliferation-inducing ability of DCs in the presence of HBeAg. (A) DC
conditions with allogenic T lymphocytes from BALB/c mice at the indicated ratios. T-cell p
Mean  S.D. of stimulation index of 5 separate experiments are shown. (B) Inhibition of MLR 
of HBeAg-treated DCs function by anti-IL-10 antibodies.
Figure 2. Effects of HBeAg on the expressions of PIR-A and PIR-B mRNA. Results are norm
PIR-B transcripts in DCs from normal or Cy-treated mice in the presence or absence of HBeAg
LPS (100ng/ml).derived DCregs has been attributed to IL-10,23 we wondered that
whether IL-10 contributed to the regulatory function of these
HBeAg treated DCs. Results showed that blockade of IL-10 by anti-
IL-10 antibody reduced the regulatory capacity of these cells by
approximately 45%(P < 0.05), indicating a partially IL-10-depen-
dent regulatory function(Fig. 3C).
3.3. Cytokines production by DC under different culture condition
It appears that IL-12 and IL-10 are both important cytokines
during the immune response to infection, which play antagonist
roles. Spontaneous IL-12 and IL-10 production of DCs is shown in
Fig. 4A. HBeAg induced statistically signiﬁcantly higher level of
IL-12 and IL-10 secretion than the controls. This study gave a result
of zero of IL-12p70 secretion of untreated iDCs, which was
consistent with the previous report.24
It has been reported that LPS stimulation induced signiﬁcant
up-regulation of cytokines including IL-12 and IL-10. As expected,
exposure of iDCs to LPS alone showed dramatic up-regulation in
the production of these two kinds of cytokines. However, when
HBeAg-treated DCs were stimulated with LPS, the increase
secretion of IL-12 was impaired (Fig. 4B). Maturation in the
presence of HBeAg may prevent the up-regulation of IL-12
secretion with the stimulation of LPS. As the expression of
cytokines is known to be up-regulated by LPS in cDCs, our
observations may indicate that HBeAg-treated DCs showed a
unique cytokine proﬁle.
3.4. PI3K-Akt plays a crucial role in HBeAg-mediated IL-12 inhibition
Previous studies have reported that phosphoinositide 3-kinase
(PI3K) exerts negative regulation on IL-12 transcription.24,25 To
investigate this signaling mechanism involved, we detected thes function was analysed in a MLR by incubating DC obtained under different culture
roliferation induced by iDCs, mDCs or DCs in the presence of HBeAg was measured.
stimulated by 104mDCs by indicated numbers of HBeAg-treated DCs. (C) Partial reversal
alized to b-actin. Each bar represents mean  S.D. (A) Expression levels of PIR-A and
. (B.C) Expression levels of PIR-A or PIR-B in DCs from different groups stimulated with
Figure 4. Effects of HBeAg on the production of IL-12 and IL-10. (A) The cell-free supernatants of different cultures were collected and analyzed for IL-12p70 and IL-10. HBeAg
induced IL-12p70 and IL-10 production in DCs. (B.C) The expression of IL-12p70 and IL-10 by DC was assessed by ELISA after the stimulation of LPS for up to 24 h. Each column
represents the mean  S.D. of four independent experiments. Statistical signiﬁcance was calculated by t-test (**P< 0.01 versus each corresponding group without LPS).
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found that the expression level of pAkt was up-regulated within
30 minutes in DCs treated with HBeAg, especially in DCs from Cy
group (Fig. 5A). Then we employed the antagonists of PI3K
signaling to the cultures. Pretreatment of PI3K inhibitor
(LY294002) could augment LPS-induced IL-12 production, where-
as the levels of IL-10 in four groups were not strikingly altered in
LY294002-pretreated DCs (Fig. 5B.C).
4. Discussion
Recent studies have shown some new mechanisms of HBV
escaping immune responses. Lang et al.26 found that HBeAg may
contribute to the pathogenesis of CHB infection via interacting and
co-localizing with TLR proteins, thus suppressing TIR-mediated
activation of both NF-kB and IFN-b. Purvina et al.27 demonstrated
that HBeAg inhibited T lymphocyte proliferation through the IL-1
signalling, which in turn aids the establishment of chronic
infection. Another study reported that HBeAg could modulate
immune responses by down-regulating IL-18 mediated expression
of IFN-g which had direct antiviral effects against HBV.28 A recent
paper has reported that HBeAg had a negative effect on the
generation of DCs.29 A high incidence of CHB in infants with
immature immune system or adults with lower immunity has
been reported. However, all the works mentioned above did not
take a look at the role of HBeAg on DCs from immunocompromised
immune status. Because the subset of regulatory DCs were
identiﬁed and considered to be important in the induction and
maintenance of immune tolerance or down-regulation of immune
response,23,30,31 we conducted experiments to elucidate whether
HBeAg can play an active role in directing the differentiation of DCs
with regulatory function propagated from bone marrow precur-
sors of normal or immunocompromised mice. Cy is a well-
described immunosuppressant which has previously been used to
induce an immunosuppressed mouse model to mimic the infected
persons with low immunity18,20 and this immunosuppressed
model has been the most practical one so far. So, this Cy-induced
immunosuppression model was chosen to examine the effect of
HBeAg on DCs in weakened immune systems.In our study, we ﬁrst demonstrated that HBeAg could induce
bone marrow-derived progenitors to differentiate into a pheno-
typically distinct DC population with high expression of CD11b and
PIR-B from both normal and Cy-treated mice. And we observed a
higher expression level of these two kinds of cellular surface
protein on the latter according to the results from ﬂow cytometric
analysis and RT-PCR experiments. In addition, Cy administration
also had great inﬂuence on the function changes of DCs incubated
with HBeAg. These data may be useful for future investigation of
the pathogenesis of CHB in the setting of immunocompromised
status, realistically mimicking clinical scenarios.
CD11b, which is highly expressed on DCregs described by Cao
XT et al.,32 may not be a speciﬁc marker for DCreg, because high
CD11b expression is also observed in other cell types like
microglial cells, macrophages and MDSCs. However, it is a
relatively stable cell molecule on the DCreg membrane according
to the previous studies.32 PIR-A/B, responsible for both speciﬁc and
nonspeciﬁc immune responses,33 is believed to play an important
role in the function regulation of DCs. PIR-B is expressed on B
lymphocytes, myeloid cells and dendritic cells, and the role played
by PIR-B in the negative regulation of immune response has been
documented.34,35 The orthologous of PIR-B in humans are
immunoglobulin-like transcript (ILT)3 and ILT4, which are critical
for DCs to acquire tolerance.36 To our knowledge, there is no report
about the expression of PIR-A/B on DCs treated with HBeAg. Our
study found that the inhibitory member PIR-B necessary for
maintaining the steady condition of DCs appeared to be dominant
compared with PIR-A, which was consistent with the previous
research reported by Zou Ping and Pereira et al.37,38 The PIR-B
expression of HBeAg treated DCs was remarkably up-regulated,
but no signiﬁcant difference in PIR-A was observed among the
groups. Thus, it was speculated that HBeAg might affect the
function of DC by up-regulation of PIR-B rather than PIR-A, thus
providing a novel molecular mechanism for DCs to acquire
tolerance. Further experiments showed that LPS could not reduce
the high expression of CD11b and PIR-B, indicating that HBeAg-
induced DCs had a relatively stable phenotype. Therefore, we
propose another possible new subset of DCreg with a distinct
phenotype, which may be involved in the induction of tolerance of
HBV.
Figure 5. PI3K signal activation was crucial for HBeAg-mediated suppression of IL-12. (A) Whole-cell lysates from DCs in different culture conditions with LPS (100ng/ml)
treatment for 30 minutes were subjected to Western blot analysis of phospho-Akt. Results are normalized to total Akt. Each column represents the mean  S.D. of three
independent experiments.*, # and § indicate higher expression of phospho-Akt than LPS, HBeAg+LPS and Cy +LPS groups, respectively and P-value signiﬁcance (P < 0.05) was
calculated by ANOVA. (B.C) LY294002 was used or not to treat DCs in different groups for 1 hour before the further stimulation of LPS (100ng/ml). And the production of IL-12p70 and
IL-10 in the cell-free supernatants was assayed by ELISA.
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their ability to promote T-cell proliferation. Thus, MLR was
conducted to determine this capacity of HBeAg-treated DCs. As
there is no effective and appropriate method to isolate both CD11b
and PIR-B positive DCs, total HBeAg-treated DCs were detected. A
clearly reduced T-cell proliferation compared to mDCs was
observed in HBeAg incubated DCs. When DC/T was 1:5 or 1:10,
DCs treated with HBeAg from immunocompromised mice tended
to have the lower T-cell stimulatory capacity as compared with
HBeAg treated cells from normal mice, suggesting that Cy might
promote the attenuation of DCs’ T-cell stimulatory activity caused
by HBeAg. But when DC/T was 1:20, there was no signiﬁcant
difference between these two HBeAg-treated groups, perhaps
because the quantity of DC was not enough to promote T-cell
proliferation. Furthermore, HBeAg treated DCs from immunocom-
promised mice are more potent inhibitors of MLR with a partially
IL-10-dependent regulatory function.
The inﬂammatory factors are believed to be involved in the
pathogenesis of CHB. HBeAg can affect key cytokine production
during the establishment of CHB.28 IL-12 is produced by DCs early
in immune response and exerts its biological function by driving
Th1 cell activation and differentiation, and the autocrine IL-10 is
involved in a regulatory mechanism in suppressing IL-12 produc-
tion in DCs.39 Here, we observed that DCs in groups with HBeAg
spontaneously released relatively a low level of IL 12p70 and a high
level of IL-10, which may be related to the potency in inhibiting a
primary MLR. And another outcome from this study was that after
the stimulation of LPS, the IL-12 production of HBeAg-treated DC
increased, but not to the same magnitude. However, the up-
regulation of IL-10 was not impaired. Therefore, it is not likely that
IL-10 was the decisive factor in the suppression of IL-12 in HBeAgtreated DCs upon stimulation with LPS.PI3K-Akt signal pathway
has been reported to play a central role in the response of DC to
environmental stimulus, including the regulation of IL-12 secre-
tion.24,25 So, in order to identify the possible mechanisms for the
impacts of HBeAg on the cytokine production of DCs, the
phosphorylation level of phosphor-Akt was measured by western
blot. We observed an enhanced expression level of phosphor-Akt
in HBeAg-treated DCs, especially in the Cy group with the highest
relative protein expression level. Pretreatment of DCs with
LY294002, the speciﬁc inhibitor of the PI3K pathway, could
signiﬁcantly augment LPS-induced IL-12 production. These data
suggest that the PI3K pathway is likely to be involved or at least
played a partial role in the HBeAg inducing down-regulation of
IL-12 production of DCs.
In conclusion, we found that HBeAg could program bone
marrow progenitors into a DC subset in vitro with considerably up-
regulated expression of CD11b and PIR-B, a decreased T-cell
stimulatory capacity and a suppressed production of IL-12. It is
worth mentioning that these phenomena were more evident in
DCs generated from Cy-treated immunocompromised mice. PI3K
signalling activation was related to the down-regulation of IL-12
secretion. Our ﬁndings provide novel information for the current
recognition of the formation of persistent HBV infection and may
cause some meaningful implications. Our experiments did not
investigate the underlying molecular mechanisms contributing to
the generation of such regulatory DCs, and we need further in vivo
experiments designed and tested to evaluate the immunosup-
pressive moderation function of HBeAg and validate the existence
of regulatory DCs in HBV transgenic mice or patients with chronic
HBV infection.
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